Neumora Therapeutics, Inc. (NMRA): Nasdaq/NYSE listing notice — Neumora receives Nasdaq minimum bid price deficiency notice; has until Nov 10, 2025 to cure

Neumora Therapeutics, Inc.

Nasdaq notified Neumora on May 14, 2025 that its stock failed to meet the $1.00 minimum bid price requirement.
Company has 180 calendar days, until November 10, 2025, to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not compliant by Nov 10, 2025, Neumora may seek transfer to Nasdaq Capital Market and additional cure period.
Board approved a reverse stock split (1-for-5 to 1-for-30) subject to stockholder vote at Annual Meeting on May 28, 2025.
Neumora intends to monitor bid price and consider options including the reverse split to maintain listing.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Neumora Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

May 14, 2025, Neumora Therapeutics, Inc. (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market, as set forth in Listing Rule 5450(a)(1). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until November 10, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00

View on SEC.gov

Browse all listing & compliance notices →

Neumora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-121714

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.